[{"id":"37515089-1ee4-4286-99b0-7bb0298fc653","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472153","created_at":"2026-03-28T01:41:57.745Z","updated_at":"2026-03-28T01:41:57.745Z","phase":"Phase 2/3","brief_title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","source_id_and_acronym":"NCT07472153","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"bf338af6-7bdc-4263-a249-2470acc07fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06860529","created_at":"2025-06-07T14:59:59.699Z","updated_at":"2025-06-07T14:59:59.699Z","phase":"Phase 2","brief_title":"Serplulimab Combined with Chemotherapy for Early-stage HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT06860529","lead_sponsor":"Henan Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • epirubicin • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 357","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-03-06"},{"id":"3a781d1f-a0ee-4f5f-a8a8-4151c22e0f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT06849518","created_at":"2025-03-03T09:58:04.227Z","updated_at":"2025-03-03T09:58:04.227Z","phase":"","brief_title":"Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer","source_id_and_acronym":"NCT06849518","lead_sponsor":"Ballad Health","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/11/2025","start_date":" 02/11/2025","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-28"},{"id":"0d632197-009b-4cc8-8b15-f154cec2fe79","acronym":"ACCIO","url":"https://clinicaltrials.gov/study/NCT04267848","created_at":"2021-01-18T20:44:14.334Z","updated_at":"2025-02-25T12:37:33.994Z","phase":"Phase 3","brief_title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial","source_id_and_acronym":"NCT04267848 - ACCIO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed • Pembroria (pembrolizumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 1210","initiation":"Initiation: 06/16/2020","start_date":" 06/16/2020","primary_txt":" Primary completion: 12/15/2025","primary_completion_date":" 12/15/2025","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2025-02-24"},{"id":"706663a7-a978-4e9d-b057-4930c92e0793","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642195","created_at":"2022-12-08T15:58:15.185Z","updated_at":"2025-02-25T12:29:14.210Z","phase":"Phase 1/2","brief_title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05642195","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant"],"overall_status":"Suspended","enrollment":" Enrollment 30","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 12/30/2033","primary_completion_date":" 12/30/2033","study_txt":" Completion: 12/30/2035","study_completion_date":" 12/30/2035","last_update_posted":"2025-02-24"},{"id":"7bf4c100-c992-4e7a-9ed8-b32c4d26ea43","acronym":"SWOG 1512","url":"https://clinicaltrials.gov/study/NCT02775851","created_at":"2021-01-18T13:36:44.518Z","updated_at":"2025-02-25T12:26:29.443Z","phase":"Phase 2","brief_title":"Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02775851 - SWOG 1512","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 02/06/2017","start_date":" 02/06/2017","primary_txt":" Primary completion: 04/14/2023","primary_completion_date":" 04/14/2023","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-02-24"},{"id":"9c7ac936-fde1-4b07-9296-dad7240ad183","acronym":"","url":"https://clinicaltrials.gov/study/NCT04963153","created_at":"2021-07-15T13:06:11.818Z","updated_at":"2025-02-25T12:28:14.832Z","phase":"Phase 1","brief_title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","source_id_and_acronym":"NCT04963153","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR2 • NECTIN4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • FGFR2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2022","start_date":" 07/07/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-24"},{"id":"b57cb3c0-4fb2-4fdc-add3-151c7aaf3f51","acronym":"SAINT","url":"https://clinicaltrials.gov/study/NCT03138161","created_at":"2024-04-18T20:51:31.500Z","updated_at":"2025-02-25T12:26:41.043Z","phase":"Phase 1/2","brief_title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT03138161 - SAINT","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 07/31/2031","study_completion_date":" 07/31/2031","last_update_posted":"2025-02-24"},{"id":"c79faf97-f729-4398-957b-5d83e409d779","acronym":"COMMIT","url":"https://clinicaltrials.gov/study/NCT02997228","created_at":"2021-01-18T14:45:08.921Z","updated_at":"2025-02-25T12:26:35.429Z","phase":"Phase 3","brief_title":"Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study","source_id_and_acronym":"NCT02997228 - COMMIT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR","tags":["PD-L1 • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/19/2018","start_date":" 01/19/2018","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-24"},{"id":"d3bfd11b-aa0d-4a68-9367-984e869fb8f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04712851","created_at":"2024-01-26T16:18:46.583Z","updated_at":"2025-02-25T12:27:53.681Z","phase":"Phase 2","brief_title":"Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia","source_id_and_acronym":"NCT04712851","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-02-24"},{"id":"e5a7e816-2338-4069-ab5a-d3e2d67f258f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04243616","created_at":"2021-01-18T20:37:50.114Z","updated_at":"2025-02-25T12:27:27.130Z","phase":"Phase 2","brief_title":"Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer","source_id_and_acronym":"NCT04243616","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PD-L1 • PGR • PD-L2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PGR positive","tags":["HER-2 • PD-L1 • PGR • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 07/14/2025","primary_completion_date":" 07/14/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-24"},{"id":"e6b99f28-6a26-4cf9-aa0c-52200cf1061c","acronym":"ECOG-ACRIN EA3202","url":"https://clinicaltrials.gov/study/NCT05063552","created_at":"2021-10-01T12:54:14.078Z","updated_at":"2025-02-25T12:28:23.682Z","phase":"Phase 2/3","brief_title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","source_id_and_acronym":"NCT05063552 - ECOG-ACRIN EA3202","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 03/13/2023","start_date":" 03/13/2023","primary_txt":" Primary completion: 12/15/2027","primary_completion_date":" 12/15/2027","study_txt":" Completion: 12/15/2027","study_completion_date":" 12/15/2027","last_update_posted":"2025-02-24"},{"id":"ec39bba5-c725-4310-a7b9-db843f8fcd99","acronym":"AdvanTIG-206","url":"https://clinicaltrials.gov/study/NCT04948697","created_at":"2021-07-02T12:52:38.466Z","updated_at":"2025-02-25T12:28:13.406Z","phase":"Phase 2","brief_title":"A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC","source_id_and_acronym":"NCT04948697 - AdvanTIG-206","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 08/20/2021","start_date":" 08/20/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2025-02-24"},{"id":"0b405f7d-3f61-4823-b79f-2d25bdb0eeb2","acronym":"SGNPDL1V-001","url":"https://clinicaltrials.gov/study/NCT05208762","created_at":"2023-05-26T17:05:40.425Z","updated_at":"2025-02-25T13:49:21.100Z","phase":"Phase 1","brief_title":"A Study of SGN-PDL1V in Advanced Solid Tumors","source_id_and_acronym":"NCT05208762 - SGNPDL1V-001","lead_sponsor":"Seagen Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PF-08046054"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 11/18/2027","primary_completion_date":" 11/18/2027","study_txt":" Completion: 11/17/2028","study_completion_date":" 11/17/2028","last_update_posted":"2025-02-21"},{"id":"4cfc5715-dc42-47d6-8b29-f4162141b070","acronym":"20-C-0012","url":"https://clinicaltrials.gov/study/NCT04235777","created_at":"2021-01-29T07:20:15.829Z","updated_at":"2025-02-25T13:40:02.108Z","phase":"Phase 1","brief_title":"Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","source_id_and_acronym":"NCT04235777 - 20-C-0012","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-21"},{"id":"8100f49e-ecbc-41b2-9130-5ed625da8fc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669496","created_at":"2025-02-25T13:40:17.235Z","updated_at":"2025-02-25T13:40:17.235Z","phase":"Phase 2/3","brief_title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors","source_id_and_acronym":"NCT04669496","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI • CEACAM5 • MUC16","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI • CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"d9249df0-7324-4379-b412-dbfbc6b5d9e8","acronym":"NAUTIKA1","url":"https://clinicaltrials.gov/study/NCT04302025","created_at":"2021-01-18T20:51:55.005Z","updated_at":"2025-02-25T13:40:05.730Z","phase":"Phase 2","brief_title":"A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04302025 - NAUTIKA1","lead_sponsor":"Genentech, Inc.","biomarkers":" PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12","tags":["PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 03/06/2029","study_completion_date":" 03/06/2029","last_update_posted":"2025-02-21"},{"id":"3bf414c0-2141-4ef6-8218-6aca96f23937","acronym":"CHECK'UP","url":"https://clinicaltrials.gov/study/NCT03412058","created_at":"2021-03-04T17:52:48.409Z","updated_at":"2025-02-25T13:52:30.402Z","phase":"","brief_title":"Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists","source_id_and_acronym":"NCT03412058 - CHECK'UP","lead_sponsor":"UNICANCER","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression • ALK negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression • ALK negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 670","initiation":"Initiation: 06/27/2018","start_date":" 06/27/2018","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-20"},{"id":"4405fdfb-3952-4954-a472-701ca7d88a54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821777","created_at":"2023-04-20T14:03:54.395Z","updated_at":"2025-02-25T13:49:46.186Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05821777","lead_sponsor":"Centessa Pharmaceuticals (UK) Limited","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itanistomig (LB101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/05/2027","study_completion_date":" 01/05/2027","last_update_posted":"2025-02-20"},{"id":"807f36c6-67b7-462d-967d-8ff2c904b129","acronym":"","url":"https://clinicaltrials.gov/study/NCT05487235","created_at":"2022-08-04T15:56:23.853Z","updated_at":"2025-02-25T13:54:37.340Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05487235","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • BRAF • ALK","pipe":" | ","alterations":" PD-L1 expression • BRAF wild-type","tags":["EGFR • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • migoprotafib (RLY-1971) • omeprazole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 232","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-20"},{"id":"84e74e03-8f34-4176-b63b-03c06eac53aa","acronym":"CodeBreaK 202","url":"https://clinicaltrials.gov/study/NCT05920356","created_at":"2023-06-27T14:08:07.537Z","updated_at":"2025-02-25T13:55:19.667Z","phase":"Phase 3","brief_title":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)","source_id_and_acronym":"NCT05920356 - CodeBreaK 202","lead_sponsor":"Amgen","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-02-20"},{"id":"bb6bfd1b-2fa4-443f-a449-16c91a04c63d","acronym":"HARMONi-3","url":"https://clinicaltrials.gov/study/NCT05899608","created_at":"2023-06-12T15:08:54.174Z","updated_at":"2025-02-25T13:55:16.855Z","phase":"Phase 3","brief_title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients","source_id_and_acronym":"NCT05899608 - HARMONi-3","lead_sponsor":"Summit Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yidafan (ivonescimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 1080","initiation":"Initiation: 10/26/2023","start_date":" 10/26/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-20"},{"id":"ce9dfb12-840f-46f6-b8d1-947639822665","acronym":"Morpheus Lung","url":"https://clinicaltrials.gov/study/NCT03337698","created_at":"2021-01-18T16:29:17.212Z","updated_at":"2025-02-25T13:48:26.615Z","phase":"Phase 1/2","brief_title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","source_id_and_acronym":"NCT03337698 - Morpheus Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-20"},{"id":"102a276a-2e7a-4a7f-a75b-c71813873058","acronym":"JS001-027-III-HCC","url":"https://clinicaltrials.gov/study/NCT04523493","created_at":"2021-01-18T21:40:02.000Z","updated_at":"2025-02-25T14:02:00.920Z","phase":"Phase 3","brief_title":"Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC","source_id_and_acronym":"NCT04523493 - JS001-027-III-HCC","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 530","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-19"}]